Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Aldesleukin 22000000 UNT Injection [Proleukin]

Known as: ALDESLEUKIN 1.1 mg in 1 mL INTRAVENOUS INJECTION [PROLEUKIN], Proleukin 22,000,000 UNT Injection, aldesleukin 1.1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Proleukin] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Regulatory T cells (Tregs) play an important role in preventing effector T-cell (Teff) targeting of self-antigens that can lead… 
2016
2016
Background: While immune checkpoint blockade is a promising therapeutic approach, combination with agents that modulate… 
2014
2014
Background SLE is characterized by the breakdown of immune tolerance towards nuclear autoantigens. Aberrant activation of… 
2014
2014
Meeting abstracts To investigate whether the sequence of HD IL-2 and a checkpoint inhibitor, Ipilimumab, will have additive or… 
2014
2014
Meeting abstracts To investigate whether the Vemurafenib-induced increased tumor antigen expression, T lymphocyte infiltration… 
2011
2011
BACKGROUND The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of… 
2004
2004
Background: Published results from studies testing two different dosing regimens of IL-2 in combination with rituximab have shown… 
2004
2004
Background: Antibody-dependent cellular cytotoxicty (ADCC) is an important mechanism of rituximab activity. Genetic polymorphisms… 
2001
2001
ZusammenfassungInterleukin-2 (IL-2) kommt aufgrund seiner immunstimulatorischen Wirkung auf T-Zellen in der Tumortherapie von… 
1994
1994
Background: On the basis of encouraging preclinical data, we investigated the combination of the 2 agents recombinant interferon…